Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, Professor of Medicine at the University of Central Florida, and at Loma Linda University Health, shared a post on LinkedIn:
“Bladder Cancer update from CheckMate-901 phase III clinical trial
The combination of nivolumab with gemcitabine-cisplatin (GC) did not worsen health-related quality of life (HRQoL). Data further support GC-nivolumab as an option for the firstline therapy of cisplatin-eligible advanced urothelial carcinoma
Pleased to coauthor in European Society for Medical Oncology (ESMO) open from Adventhealth Cancer Institute, AdventHealth Central Florida, University of Central Florida – along with Jens Bedke, Michiel van der Heijden, Matthew Galsky, Tom Powles – sponsored by Bristol Myers Squibb”
Title: Nivolumab plus gemcitabine–cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial
Authors: J. Bedke, M.S. van der Heijden, G. Sonpavde, M.D. Galsky, W. Liao, L. Shi, S.I. Blum, S. Mitra, M.Y. Patel, T. Powles.
Other articles featuring Guru Sonpavde on OncoDaily.